Regarding ALK genomic subtype, 3–7% of NSCLC patients present an activated form of ALK, formed by a gene fusion event between ALK and the echinoderm microtubule-associated protein-like 4 (EML4). The gene discussed is ALK; the disease is non-small cell lung carcinoma.